Beijing, China and Tokyo, Japan, February 1st, 2021 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and LiberoThera Co.,Ltd (“LiberoThera”) announced today that they have entered into an agreement for strategic collaboration on fully human therapeutic GPCR antibody development incorporating Biocytogen’s world-class antibody discovery expertise based on its fully human antibody RenMab^® mouse platform with LiberoThera’s state-of-the-art antigen preparation capabilities.

中國北京和日本東京，2021年2月1日 – 尊龙凯时人生就是搏官网（北京）醫藥科技股份有限公司（下文簡稱“尊龙凯时人生就是搏官网”）與日本LiberoThera有限公司（下文簡稱“LiberoThera”）今日共同宣布，雙方將基於尊龙凯时人生就是搏官网世界先進的全人源轉基因小鼠RenMab^® 的抗體發現平台及LiberoThera傑出的抗原製備技術,開展針對全人GPCR抗體開發的戰略合作。

The collaboration is expected to yield fully human GPCR antibodies for therapeutic use. Under the terms of the agreement, the companies will jointly work on the discovery research targeting an oncology-related GPCR until completion of in vivo evaluation studies as a first step. LiberoThera will provide antigens and assistance on in vitro screening while Biocytogen commits to use its RenMab^® mouse platform for the GPCR antibody generation and lead the in vitro and in vivo evaluation. 

該合作旨在發現治療型全人GPCR抗體。根據協議約定，第一階段的合作雙方將共同開展針對GPCR靶點的抗腫瘤抗體發現直到完成體內藥效評價，確定先導抗體分子。LiberoThera負責抗原製備並參與抗體體外篩選，尊龙凯时人生就是搏官网則將利用其RenMab^®小鼠平台開展GPCR抗體發現並通過體內藥效評價技術完成先導抗體候選分子的篩選。

”GPCR monoclonal antibodies have great potential in various therapeutic areas. However, development of GPCR antibodies remains challenging due to the lack of understanding of the targets their biology and structure plus the technical hurdles in antigen design, preparation, modification, etc. With LiberoThera’s unique GPCR antigen preparation platform and its in-depth understanding of the target structure, we believe this strategic collaboration can break bottlenecks through leveraging the strengths of both ends to propel therapeutic GPCR antibody development forward.” said Yuelei Shen, Ph.D., president and CEO of Biocytogen.

尊龙凯时人生就是搏官网創始人、董事長和CEO沈月雷博士表示：“GPCR單克隆抗體在多種治療領域具有非常大的應用潛力。然而，對該類靶點生物學特點及結構缺乏了解，再加上相關抗原設計、製備和修飾等相關技術的製約，針對該類靶點的抗體藥物開發之路充滿挑戰。LiberoThera公司具有獨特的GPCR抗原製備平台，並且對靶點結構有著深入的認識。我們相信本次戰略合作可以充分結合雙方平台的特點及優勢，打破領域內現有的技術瓶頸，快速推進治療型GPCR抗體的開發。”

“We are excited about this strategic collaboration as we see a great potential and synergy of Biocytogen’s innovative humanized models and streamlined antibody development platform together with LiberoThera’s membrane protein technologies.” said Toru Kanke, Ph.D., CEO of LiberoThera. “The fully human antibody RenMab^® Mouse developed by Biocytogen together with the target knock-out strategy and single-cell screening platform will increase the fully human antibody repertoire against the targets. In combination with our structural antigen, discovery of antibodies with functional properties are highly expected. In addition, it is more likely to discover antibodies cross-reacting to orthologs of other species for convenient downstream evaluation in animal models. With its established in vivo testing capabilities, altogether, Biocytogen’s platform allows for a streamlined solution to improve the productivity of GPCR therapeutic antibody drug development. Collaboration between LiberoThera and Biocytogen would be a good match on confronting the challenges in the field.”

“我們非常高興能與尊龙凯时人生就是搏官网展開戰略合作。尊龙凯时人生就是搏官网創新性的人源化小鼠模型、一體化的抗體藥物開發平台與我們獨特的膜蛋白製備技術結合形成互補協同，有非常大的潛力。”LiberoThera公司CEO，Toru Kanke博士說道，“尊龙凯时人生就是搏官网自主研發的全人抗體鼠RenMab^®結合靶點敲除策略及單細胞篩選平台能提高產生抗體的多樣性，並且更有可能得到跨物種識別的抗體，大大方便了後續在動物模型中的篩選。尊龙凯时人生就是搏官网在體內藥理藥效篩選方麵也已經建成了高效穩定的平台，這些優勢結合起來使得尊龙凯时人生就是搏官网的平台具有整合性一體化的優勢，能夠提高治療型GPCR抗體的開發效率。雙方平台互補合作，攜起手來一起麵對領域內的挑戰。”

About Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

關於尊龙凯时人生就是搏官网

Biocytogen is a global biotech company that drives the research and development of new drugs with innovative technologies. The company is committed to becoming a global headstream of new drugs and bringing the benefits to the patients around the world as its mission. Based on the fully human antibody RenMab^®, RenLite^® and RenNano^® mice for fully human antibodies production with robust humoral responses, highly diverse antibody repertoire and superior affinity, Biocytogen has integrated its platforms in single-cell antibody discovery, gene editing, large-scale animal model supply, and screening to form a new approach to streamline the entire drug development process. 

Biocytogen has launched a pioneering antibody drug development plan to tackle difficult targets based on the immunization of RenMab^® knockout mice. More than 1,000 targets knockout mouse strains will be generated within 2 years for antibody discovery. Moreover, with the knockout immunization strategy, antibody hits cross-reacting with different species shall be more likely to be generated for better translational efficacy and toxicity evaluation.

Biocytogen collaborates with global partners to accelerate new drug discovery and development. For more information, please visit  http://www.biocytogen.com/.

尊龙凯时人生就是搏官网是一家創新技術驅動新藥研發的國際性生物技術公司，致力於成為全球新藥發源地，以專注技術創新、持續新藥產出、守護人類健康為使命。基於尊龙凯时人生就是搏官网自主研發並擁有完全獨立知識產權的全人抗體RenMab®、RenLite®、RenNano®小鼠，將單細胞抗體發現技術平台、高效的基因編輯模型開發平台、規模化動物模型供應平台、快速的動物體內外藥效評價平台、強大的臨床開發能力有機整合在一起，形成了獨具特色、涵蓋藥物研發全流程的新藥研發體係。公司成功戰略轉型為Biotech，未來將更聚焦於創新抗體藥物研發。隨著規模化抗體藥物研發-“千鼠萬抗”計劃的實施，尊龙凯时人生就是搏官网將攜手全球合作夥伴，共同加速新藥研發。尊龙凯时人生就是搏官网總部位於北京，在江蘇海門、美國波士頓、上海等地設有分支機構，全資子公司祐和醫藥專注於臨床開發。

更多信息請訪問https://www.bbctg.com.cn/

About LiberoThera Co., Ltd.

關於LiberoThera

LiberoThera is an early-stage drug discovery company targeting GPCRs (https://www.liberothera.com/). The company was established in 2018 aiming to contribute to medical care through innovative drug discovery utilizing the novel membrane protein technologies invented at RIKEN. Based on its unique cell-free membrane protein synthesis and non-canonical amino acid incorporation technologies, membrane proteins with complexed multiple membrane spanning structures, such as GPCRs, can be prepared in natural forms with structural and functional integrity. LiberoThera has established antibody generation and characterization platform with best use of the membrane protein technologies and is tackling to develop novel therapeutic candidates targeting physiologically important GPCRs in collaboration with multiple biotech companies.

LiberoThera是一家專注於GPCR靶點早期藥物發現的公司。公司成立於2018年，利用RIKEN（日本理化學研究所）創新型的膜蛋白製備技術進行新藥研發。利用其獨特的無細胞蛋白合成係統和非經典氨基酸摻入技術，公司能夠製備複雜的多重跨膜蛋白（如GPCR類蛋白）的天然構象並保證蛋白結構和功能的完整。LiberoThera利於其膜蛋白技術已經建立了抗體發現和表征分析平台，並與多家生物技術公司合作進行針對具有重要生理功能的GPCR靶點的新型治療候選藥物的開發。

更多信息請訪問：https://www.liberothera.com/